Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase NA 1Phase 1/2 1

Status

Completed 4Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 7

Study Type

Interventional 7

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

rozanolixizumab 10zilucoplan 8efgartigimod alfa 8Rituximab 7Cyclophosphamide 7telitacicept 6fludarabine 6eculizumab 5Prednisone 5ravulizumab 4Pyridostigmine Bromide 4Immunoglobulins, Intravenous 4Hizentra 4Tacrolimus 3Mycophenolic Acid 3HBM9161 3Amifampridine 3thymoglobulin 2inebilizumab 2Prednisolone 2Exercise 2tofacitinib 1tocilizumab 1talquetamab 1satralizumab 1sargramostim 1rhoA GTP-Binding Protein 1remibrutinib 1prednylidene 1iscalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Myasthenia Gravis × Rituximab × Clear all
NCT05868837 2025-08-01

REFINE

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 3 Recruiting
40 enrolled

Myasthenia Gravis

NCT07071246 2025-07-17

Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis

Tang-Du Hospital

Phase NA Active not recruiting
30 enrolled

Myasthenia Gravis

NCT02950155 2024-10-26

Rinomax

Karolinska Institutet

Phase 3 Completed
47 enrolled 24 charts

Myasthenia Gravis

NCT05332587 2022-05-02

Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis

First Affiliated Hospital, Sun Yat-Sen University

Phase 3 Unknown
50 enrolled

Myasthenia Gravis

NCT02110706 2020-03-06

BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis

Yale University

Phase 2 Completed
52 enrolled 18 charts

Myasthenia Gravis

NCT00619671 2013-01-16

A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

University of Vermont

Phase 1/2 Completed
10 enrolled

Myasthenia Gravis

NCT00774462 2012-12-11

FORCE

Assistance Publique - Hôpitaux de Paris

Phase 2 Completed
30 enrolled

Myasthenia Gravis, Myositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡